TARSUS PHARMACEUTICALS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- TARSUS PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $1.86M, a 54.69% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $1.20M, a 16.21% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $2.56M, a 255.34% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $1.21M, a 33.72% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $6.28M, a 11.96% increase from fiscal 2024.
- TARSUS PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $5.61M, a 847.47% increase from fiscal 2023.
- TARSUS PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $592.00K, a 381.30% increase from fiscal 2022.
- TARSUS PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $123.00K, a 19.42% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $1.86M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $1.20M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $6.28M 10-K · filed 2026-02-23 | |
| 2025-09-30 | $2.56M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $1.21M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $1.44M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $5.61M 10-K · filed 2026-02-23 | |
| 2024-09-30 | $721.00K 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $1.82M 10-Q · filed 2025-11-04 | |
| 2024-03-31 | $802.00K 10-Q · filed 2025-11-04 | |
| 2023-12-31 | $592.00K 10-K · filed 2026-02-23 | |
| 2023-09-30 | $516.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $45.00K 10-Q · filed 2024-11-13 | |
| 2023-03-31 | $13.00K 10-Q · filed 2024-11-13 | |
| 2022-12-31 | $123.00K 10-K · filed 2025-02-25 | |
| 2022-09-30 | $82.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $17.00K 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $103.00K 10-K · filed 2023-03-17 | |
| 2021-09-30 | $174.00K 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $1.00K 10-Q · filed 2022-11-09 | |
| 2021-03-31 | $19.00K 10-Q · filed 2022-11-09 | |
| 2020-12-31 | $10.00K 10-K · filed 2022-03-14 | |
| 2020-09-30 | $6.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |